Ignite Creation Date:
2025-12-24 @ 2:13 PM
Ignite Modification Date:
2026-02-06 @ 2:38 PM
Study NCT ID:
NCT02650895
Status:
COMPLETED
Last Update Posted:
2023-01-12
First Post:
2016-01-06
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)
Sponsor:
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-06-02
Start Date Type:
ACTUAL
Primary Completion Date:
2015-01-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2015-01-15
Completion Date Type:
ACTUAL
First Submit Date:
2016-01-06
First Submit QC Date:
None
Study First Post Date:
2016-01-08
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-11-27
Results First Submit QC Date:
None
Results First Post Date:
2020-01-29
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-01-11
Last Update Post Date:
2023-01-12
Last Update Post Date Type:
ACTUAL